Overcoming resistance to DNA damaging agents often involves combination therapy, where drugs with different mechanisms of action are used together. This can help to target multiple pathways involved in cancer cell survival. Additionally, research into biomarkers that predict response to DNA damaging agents is ongoing, with the goal of personalizing therapy to the genetic makeup of individual tumors. PARP inhibitors are an example of a targeted approach that specifically exploits deficiencies in DNA repair pathways in certain cancers.
